logo
logo
Search For Features
/
StocksStocks
Intraday BoosterIntraday Booster
Sector BoosterSector Booster
Stock ScreenerStock Screener
Market PulseMarket Pulse
ScreenersScreeners
MoreMore
prime iconGo Prime
My PlansMy Plans
Privacy PolicyPrivacy Policy
ContactContact
Refer & EarnRefer & Earn
ScreenersScreeners
Main
Stock ScreenerStock Screener
Create ScreenerCreate Screener
Explore ScreenersExplore Screeners
Community ScreenersCommunity Screeners
Trading Screeners
CandleSticks ScreenerCandleSticks Screener
Top Gainers & LosersTop Gainers & Losers
Opening Range BreakoutOpening Range Breakout
Stock Screener AIStock Screener AI
Stock Quality ScorecardStock Quality Scorecard
Overvalued StocksOvervalued StocksNew
Undervalued StocksUndervalued StocksNew
Technical Screeners
NR4 StocksNR4 Stocks
NR7 StocksNR7 Stocks
Previous Day High BreakoutPrevious Day High Breakout
Previous Day Low BreakoutPrevious Day Low Breakout
Previous Day Open BreakoutPrevious Day Open Breakout
Bullish Crossover StocksBullish Crossover Stocks
Bearish Crossover StocksBearish Crossover Stocks
High Volume ShockerHigh Volume Shocker
VWAP Breakout StocksVWAP Breakout Stocks
Range High BreakoutRange High Breakout
Range Low BreakoutRange Low Breakout
MoreMore
Markets
Global Market TodayGlobal Market Today
Global IndicesGlobal Indices
Indian IndicesIndian Indices
NIfty TodayNIfty Today
Smart Money
FII DII DataFII DII DataNew
FII BuyingFII Buying
NSE Insider TradingNSE Insider Trading
SLB Stocks DataSLB Stocks Data
Derivatives
FnO MovementsFnO Movements
NSE F&O Lot SizeNSE F&O Lot Size
Ban ListBan List
Analysis & Calendars
Technical DashboardTechnical Dashboard
Sector BoosterSector Booster
Sector AnalysisSector AnalysisNew
Result CalendarResult Calendar
Economic CalendarEconomic Calendar
Astrazeneca Pharma India Ltd

Astrazeneca Pharma India

Large Cap•800 Employees•IPO 1998
Current Price
₹8575.00
-34 (-0.39%)Updated
NSE :ASTRAZEN
BSE :506820
Sector :Pharmaceuticals
Today's Range
8575
₹8575.00
indicator
8575
52 Week Range
52W Low₹7201.15
52W High₹10691.00
₹8575.00
indicator
Downside19.08%
Upside24.68%
chart iconChart

Price Chart

Compare with Peers

Historical Ratios

Track top 12 most important financial ratios

P/E Ratio: Price to Earnings - Most used valuation metric

Loading chart...

Analyzing Investment Quality

Processing 9 key metrics...

Key Metrics

Hover for details

Valuation

Market Cap
₹22,303.13 Cr
Market Cap
Total market value of company
P/E Ratio
111.99
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)
P/B Ratio
28.49
P/B Ratio
Price to Book Value. <3 may indicate undervaluation
EPS
₹79.68
EPS
Earnings Per Share. Higher and growing is positive

Profitability

ROE
14.33%
ROE
Return on Equity. >15% is good, >20% is excellent
ROCE
33.40%
ROCE
Return on Capital Employed. >15% is good
Net Margin
9.93%
Net Margin
Net profit as % of revenue. >10% is good
Operating Margin
-%
Operating Margin
Operating profit margin. >15% is good

Growth

EPS Growth (5Y)
9.89%
EPS Growth (5Y)
5-year EPS growth. >15% is strong
Revenue Growth (5Y)
15.59%
Revenue Growth (5Y)
5-year revenue growth. >10% is good
Qtr Sales Growth
35.80%
Qtr Sales Growth
Quarter-over-quarter sales growth
Qtr Profit Growth
60.10%
Qtr Profit Growth
Quarter-over-quarter profit growth

Financial Health

Debt/Equity
0.05
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellent
Book Value
₹308.14
Book Value
Net asset value per share
Dividend Yield
0.36%
Dividend Yield
Annual dividend as % of price. >2% is good
Promoter Holding
75.00%
Promoter Holding
Promoter stake. >50% shows confidence
Good
Average
Needs Attention

SWOT Analysis

Strengths

5 points
  • •Robust profitability: ROE 23.6%, ROCE 33.4% indicate efficient capital utilization.
  • •Strong quarterly growth: Sales up 35.8%, profits surged 60.1% recently.

Weaknesses

5 points
  • •Elevated PE ratio of 125.51 suggests potential overvaluation compared to earnings.
  • •Historical net profit volatility, including negative Q2 2024, raises consistency concerns.

Opportunities

5 points
  • •Increasing FII and DII holdings signal growing institutional investor confidence.
  • •Well-positioned in growing Pharmaceuticals/Healthcare sector, driven by demographic trends.

Threats

5 points
  • •Intense competition in the pharmaceutical sector could pressure market share.
  • •Premium valuation (PE 125.51) risks correction if earnings growth falters.

Segment-wise Financial Analysis

Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...

Shareholding Pattern

Loading shareholding data...

Company Insider Trading Activity

No insider trading data available

Corporate Action

Company Announcements

Technical Analysis & Indicators

Standard pivot points - most widely used

Pivot Points (CLASSIC)

LevelPriceDistance% Change
R4₹8575.00+₹0.00+0.00%
R3₹8575.00+₹0.00+0.00%
R2₹8575.00+₹0.00+0.00%
R1₹8575.00+₹0.00+0.00%
PIVOT₹8575.000.000.00%
CURRENT₹8575.00--
S1₹8575.00-₹0.00-0.00%
S2₹8575.00-₹0.00-0.00%
S3₹8575.00-₹0.00-0.00%
S4₹8575.00-₹0.00-0.00%
CPR Levels
Support
Resistance
S4
S3
S2
S1
| CPR |
BC: N/AP: N/ATC: N/A
R1
R2
R3
R4
indicator
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment

is trading CPR, indicating

● CPR Width

CPR is

● Opening Range

Day's range: ~

● Price Position

Trading Inside opening range

Delivery Volume Analysis & Trading Activity

Latest Volume
0.03L
(12 Mar 2026)
-58.7% vs avg
Delivery %
42.4%
(12 Mar 2026)
-4.3% vs avg
Avg Volume (20D)
0.06L
(12 Feb - 12 Mar)
20-day average
Avg Delivery %
46.8%
(12 Feb - 12 Mar)
Trend ↑
Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.

Peer Comparison & Industry Benchmarking

Quick Compare

Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Acutaas Chemicals Ltd
93.50 %
Highest Dividend Yield
Pfizer Ltd
3.28 %

Peer Comparison

Company Name
ACUTAAS
Acutaas Chemicals Ltd
AJANTPHARM
Ajanta Pharma Ltd
APLLTD
Alembic Pharmaceuticals Ltd
COHANCE
Cohance Lifesciences Ltd
EMCURE
Emcure Pharmaceuticals Ltd
ERIS
ERIS Lifesciences Ltd
GLAND
Gland Pharma Ltd
JBCHEPHARM
J B Chemicals & Pharmaceuticals Ltd
JUBLPHARMA
Jubilant Pharmova Ltd
NATCOPHARM
Natco Pharma Ltd
NEULANDLAB
Neuland Laboratories Ltd
PFIZER
Pfizer Ltd
PPLPHARMA
Piramal Pharma Ltd
SUNPHARMA
Sun Pharmaceutical Industries Ltd
WOCKPHARMA
Wockhardt Ltd

About

ASTRAZEN

Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited is a prominent biopharmaceutical company operating in India and globally. Its core business revolves around the manufacturing, distribution, and marketing of a diverse portfolio of pharmaceutical products. This encompasses a wide range of therapeutic areas, showcasing the company's significant presence in the global healthcare market.

A major portion of AstraZeneca Pharma India's business focuses on cardiovascular, renal, and metabolic diseases. Key products in this segment include CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL, all of which target specific needs within these therapeutic areas. The company's commitment to addressing these prevalent health concerns is a key aspect of its business strategy.

Oncology represents another significant pillar of AstraZeneca Pharma India's operations. The company manufactures and sells a variety of oncology medicines under well-known brand names such as TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex. These medications target different types of cancers and contribute significantly to the company's revenue and its standing within the oncology treatment landscape.

Beyond cardiovascular and oncology, AstraZeneca Pharma India also caters to the rare diseases market with its Koselugo brand. The company's involvement in this area demonstrates a commitment to providing treatments for less common but equally significant health conditions. Further diversifying its portfolio, AstraZeneca Pharma India offers respiratory medicines such as Symbicort and Fasenra, addressing another significant area of healthcare needs.

In addition to its core product lines, AstraZeneca Pharma India also provides clinical trial services. This aspect of the business underscores the company's commitment to research and development, allowing them to contribute not just through marketed products but also through participation in the advancement of medical knowledge and treatment options. The company's offerings extend to diabetes and immunology diseases, further demonstrating the breadth of its therapeutic reach.

Established in 1979 and headquartered in Bengaluru, India, AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. This connection to a larger global entity provides access to resources, expertise, and market reach, contributing to its success in the competitive pharmaceutical industry.

COMPANY FACTS - ASTRAZEN

Registered Address

Block N1, 12th Floor,, Manyata Empassy Business Park, Rachenahalli, Outer Ring Road,

Bangalore

KARNATAKA

IN

Tel: 918067748000

Website:https://www.astrazeneca.in/

Investor Relations:http://www.astrazeneca.in/investor-relations.html
Company Details

Group: Pharmaceuticals, Biotechnology & Life Sciences

Sector: Health Care

Industry: Pharmaceuticals

Exchange: NATIONAL STOCK EXCHANGE OF INDIA

Employees: 800

IPO Date: 30/07/1998

MANAGEMENT - ASTRAZEN

Ms. Shilpa Nirula

Chairperson of the Board

Mrs. Bhavana Agrawal

Chief Financial Officer, Whole-time Director

Ms. Manasa Rama

Compliance Officer, Company Secretary

Dr. Sanjeev Panchal

Managing Director, Executive Director

Ms. Hooi-Bien Chuah

Non-Executive Director

Mr. Jesus Javier Esteso

Non-Executive Director

Ms. Sylvia Lorena Varela Ramon

Non-Executive Director

Ms. Monica Widhani

Independent Director

Ms. Revathy Ashok

Non-Executive Independent Director

Investor Questions Answered

Astrazeneca Pharma India Ltd (ASTRAZEN) Stock FAQs

Get answers to the most common questions about Astrazeneca Pharma India Ltd stock price, fundamentals, financial metrics, and investment analysis

The current share price of Astrazeneca Pharma India Ltd (ASTRAZEN) is ₹8,575. Today, the stock has declined by ₹34.00 (0.39%), trading in a range of ₹8,575 to ₹8,575. The stock opened at ₹8,575 with a trading volume of 12 shares.
Astrazeneca Pharma India Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹22,303.13 crores, P/E ratio of 111.99, ROE of 14.33%, and ROCE of 33.40%. The dividend yield stands at 0.36%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Astrazeneca Pharma India Ltd (ASTRAZEN) is ₹10,691, while the 52-week low is ₹7,201.15. Currently trading at ₹8,575, the stock is 39.4% away from its 52-week low and 19.8% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Astrazeneca Pharma India Ltd stock at ₹8,575 depends on multiple factors. The stock is currently trading with a P/E ratio of 111.99 and P/B ratio of N/A. Today's performance shows a loss of 0.39%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Astrazeneca Pharma India Ltd offers a dividend yield of 0.36%, which means for every ₹100 invested at the current price of ₹8,575, you can expect to receive approximately ₹0.36 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Astrazeneca Pharma India Ltd's key financial metrics include: P/E Ratio: 111.99, P/B Ratio: N/A, ROE: 14.33%, ROCE: 33.40%, Dividend Yield: 0.36%, EPS: ₹79.68, Book Value: ₹308.14, Debt-to-Equity: 0.05, and Current Ratio: N/A. The company's market cap stands at ₹22,303.13 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Astrazeneca Pharma India Ltd stock opened at ₹8,575 and is currently trading at ₹8,575, showing a decline of ₹34.00 (0.39%). The intraday high is ₹8,575 and low is ₹8,575. The trading volume stands at 12 shares, indicating moderate market participation today.
Astrazeneca Pharma India Ltd has a Price-to-Earnings (P/E) ratio of 111.99, which means investors are willing to pay ₹111.99 for every ₹1 of earnings. With an EPS of ₹79.68, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Astrazeneca Pharma India Ltd has a market capitalization of ₹22,303.13 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹8,575) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Astrazeneca Pharma India Ltd has a book value of ₹308.14 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹8,575, which is 2682.8% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Astrazeneca Pharma India Ltd has a Return on Equity (ROE) of 14.33% and Return on Capital Employed (ROCE) of 33.40%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These are moderate returns, suggesting decent operational efficiency. Higher percentages generally indicate better financial performance.
Astrazeneca Pharma India Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Astrazeneca Pharma India Ltd has a debt-to-equity ratio of 0.05, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Astrazeneca Pharma India Ltd has an Earnings Per Share (EPS) of ₹79.68, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹8,575 and P/E ratio of 111.99, investors are paying 111.99 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Astrazeneca Pharma India Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Astrazeneca Pharma India Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Astrazeneca Pharma India Ltd stock, consider: 1) Fundamental Analysis - Review P/E (111.99), ROE (14.33%), debt-to-equity (0.05), and growth rates. 2) Technical Analysis - Check 52-week range (₹7201.15 - ₹10691.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹8575.00) with book value (₹308.14) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Astrazeneca Pharma India Ltd share is ₹2.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹8,575 is 428650x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Astrazeneca Pharma India Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹7201.15 - ₹10691.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.05 indicates leverage. 4) Liquidity Risk - Based on trading volume of 12 shares. 5) Valuation Risk - P/E of 111.99 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Astrazeneca Pharma India Ltd operates in the industry with key metrics: P/E ratio of 111.99, ROE of 14.33%, market cap of ₹22,303.13 crores, and dividend yield of 0.36%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.05), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Astrazeneca Pharma India Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹8,575, with a 52-week range of ₹7201.15 to ₹10691.00. Based on fundamentals like P/E (111.99), ROE (14.33%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Astrazeneca Pharma India Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹8575.00. 2) Fundamental Deterioration - Declining ROE (currently 14.33%), increasing debt (D/E: 0.05), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Astrazeneca Pharma India Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.36%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.